Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young Ho | - |
dc.contributor.author | Choi, Sung Jae | - |
dc.contributor.author | Ji, Jong Dae | - |
dc.contributor.author | Song, Gwan Gyu | - |
dc.date.accessioned | 2021-09-03T21:22:36Z | - |
dc.date.available | 2021-09-03T21:22:36Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-08 | - |
dc.identifier.issn | 1462-2416 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/87896 | - |
dc.description.abstract | Aim: The aim of the current study was to investigate whether FCGR polymorphisms are associated with responsiveness to anti-TNF-alpha therapy in patients with spondyloarthropathy, psoriasis, and Crohn's disease. Materials & methods: We conducted a meta-analysis to evaluate the association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to TNF blockers. Results: The meta-analysis indicated that responsiveness to TNF blockers was associated with the FCGR3A V allele (odds ratio: 3.308; 95% CI: 1.053-10.39; p = 0.040) and the FCGR2A RR + RH genotype (odds ratio: 3.904; p = 0.027) in patients with a follow-up time of >= 6 months. Conclusion: FCGR3A V and FCGR2A R allele carriers show better responsiveness to anti-TNF-alpha therapy in patients with follow-up times >= 6 months. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | FUTURE MEDICINE LTD | - |
dc.subject | TUMOR-NECROSIS-FACTOR | - |
dc.subject | ALPHA GENE POLYMORPHISMS | - |
dc.subject | FC-GAMMA RECEPTORS | - |
dc.subject | RHEUMATOID-ARTHRITIS | - |
dc.subject | THERAPEUTIC RESPONSE | - |
dc.subject | BIOLOGICAL RESPONSE | - |
dc.subject | CLINICAL-RESPONSE | - |
dc.subject | PREDICT RESPONSE | - |
dc.subject | IMMUNE-SYSTEM | - |
dc.subject | INFLIXIMAB | - |
dc.title | Associations between functional FCGR2A R131H and FCGR3A F158V polymorphisms and responsiveness to TNF blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young Ho | - |
dc.contributor.affiliatedAuthor | Choi, Sung Jae | - |
dc.contributor.affiliatedAuthor | Ji, Jong Dae | - |
dc.contributor.affiliatedAuthor | Song, Gwan Gyu | - |
dc.identifier.doi | 10.2217/pgs.16.27 | - |
dc.identifier.scopusid | 2-s2.0-84982091422 | - |
dc.identifier.wosid | 000382319300009 | - |
dc.identifier.bibliographicCitation | PHARMACOGENOMICS, v.17, no.13, pp.1465 - 1477 | - |
dc.relation.isPartOf | PHARMACOGENOMICS | - |
dc.citation.title | PHARMACOGENOMICS | - |
dc.citation.volume | 17 | - |
dc.citation.number | 13 | - |
dc.citation.startPage | 1465 | - |
dc.citation.endPage | 1477 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | TUMOR-NECROSIS-FACTOR | - |
dc.subject.keywordPlus | ALPHA GENE POLYMORPHISMS | - |
dc.subject.keywordPlus | FC-GAMMA RECEPTORS | - |
dc.subject.keywordPlus | RHEUMATOID-ARTHRITIS | - |
dc.subject.keywordPlus | THERAPEUTIC RESPONSE | - |
dc.subject.keywordPlus | BIOLOGICAL RESPONSE | - |
dc.subject.keywordPlus | CLINICAL-RESPONSE | - |
dc.subject.keywordPlus | PREDICT RESPONSE | - |
dc.subject.keywordPlus | IMMUNE-SYSTEM | - |
dc.subject.keywordPlus | INFLIXIMAB | - |
dc.subject.keywordAuthor | FCGR polymorphism | - |
dc.subject.keywordAuthor | responsiveness | - |
dc.subject.keywordAuthor | spondyloarthropathy | - |
dc.subject.keywordAuthor | TNF blockers | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.